Mr. Brook Riggins reports

THIOGENESIS CLOSES OVERSUBSCRIBED NON-BROKERED PRIVATE PLACEMENT FOR GROSS PROCEEDS OF C$9.07 MILLION

Further to Thiogenesis Therapeutics Corp.'s news releases of May 11 and June 1, 2026, it has completed an oversubscribed non-brokered private placement through the issuance of 18,143,700 common shares at a price of 50 cents per offered share for gross proceeds of $9,071,850. All securities issued in connection with the offering are subject to a four-month-plus-one-day hold period ending Oct. 2, 2026. The offering has received conditional acceptance from the TSX Venture Exchange and remains subject to final acceptance.

In connection with the offering, the company paid certain qualified finders: (i) a cash finder's fee equal to 7 per cent of the gross proceeds raised from subscribers introduced by such finders, and (ii) non-transferable finders' options equal to 7 per cent of the offered shares issued to such subscribers. Each finder's option entitles the holder to acquire one common share at a price of 60 cents per share for a period of three years. In total, the company paid $561,529.50 in finders' fees and issued 780,059 finders' options.

An independent director of the company participated in the offering and acquired 150,000 offered shares. The issuance to such insider constitutes a related party transaction under Multilateral Instrument 61-101. The company relied on exemptions from the formal valuation and minority shareholder approval requirements in accordance with MI 61-101 and applicable policies of the TSX Venture Exchange.

Net proceeds from the offering will be used to advance the clinical development of TTI-0102, including an investigator-initiated study in cystinosis and a phase 2a clinical study in Leigh syndrome spectrum, together with formulation and manufacturing activities, regulatory engagement, and general working capital and corporate purposes.

In connection with the offering, the company engaged Bloom Burton Securities Inc. as a financial and strategic adviser on a non-exclusive basis. Bloom Burton provided advisory services to the company in respect of the oversubscribed offering. The company paid Bloom Burton Securities a cash fee of $50,000 for its advisory services. Bloom Burton Securities does not own any securities of the company.

About Thiogenesis Therapeutics Corp.

Based in San Diego, Calif., Thiogenesis Therapeutics is a clinical-stage biotechnology company developing TTI-0102, a novel once-daily, controlled-release cysteamine prodrug designed to improve tolerability and dosing relative to existing therapies. The company is focused on TTI-0102 in nephropathic cystinosis, where it is in late-stage development. The company is also planning to conduct a phase 2a clinical study in Leigh syndrome spectrum disorders.

We seek Safe Harbor.